number 114798-26-4ATC code C09CA01PubChem 3961DrugBank APRD00052Chemical dataFormula C22H23ClN6OMol. mass 422.91SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 25–35%Metabolism Hepatic (CYP2C9, CYP3A4)Half life 1.5–2 hoursExcretion Renal cozaar 25 mg biliary.

or stroke), with a low dose thiazide diuretic, invariably hydrochlorothiazide, to counteract the increase in renin cozaar 25 mg to achieve an additive antihypertensive effect. The cozaar 25 mg combination preparation is marketed by Merck under the trade name Cozaar.Contents [hide]1 Clinical use1.1 Combination with diuretic2 Pharmacokinetics3 Research4 Mechanism of action cozaar 25 mg pharmacological actions5 References6 See also[edit] Clinical useMain article: Angiotensin II receptor cozaar 25 mg with all angiotensin II receptor antagonistAs with all angiotensin II receptor type 1 (AT1) cozaar 25 mg antagonist, reducing the end organ responses to angiotensin cozaar 25 mg Losartan administration results in a decrease in total peripheral resistance (afterload) and cardiac venous return (preload) All of the status of the proven effectivity and lower costs of thiazide diuretics and beta blockers, losartan may be used first-line cozaar 25 mg patients with increased cardiovascular risk. The LIFE study demonstrated that losartan was.

formulation with a significant reduction in blood pressure (hypertension). Losartan was the first.